Paper Review Records
All Paper Review Records
25 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
117
days
Long‐term outcomes and patterns of failure in patients with thymic malignancies treated with surgery and radiation therapy
Authors
Oded Icht; Inbar Nardi‐Agmon; Paaladinesh Thavendiranathan; Shaf Keshavjee; Amiya Agrawal; John‐Michael Miro; Omar Badran; Geoffrey Liu; Xiang Y. Ye; B. C. John Cho; Andrea Bezjak; Andrew HopeShow moreShow less
Affiliations
1. Radiation Medicine Program Princess Margaret Cancer Centre University Health Network Toronto Ontario Canada; 2. Department of Radiation Oncology University of Toronto Toronto Ontario Canada; 3. Gray Faculty of Medical and Health Sciences Tel‐Aviv University Tel‐Aviv Israel; 4. Department of Medicine Division of Cardiology Ted Rogers Program in Cardiotoxicity Prevention Peter Munk Cardiac Center Toronto General Hospital University Health Network University of Toronto Toronto Ontario Canada; 5. Division of Thoracic Surgery University of Toronto Toronto General Hospital and Princess Margaret Cancer Centre University Health Network Toronto Ontario Canada; 6. Department of Medical Oncology Princess Margaret Cancer Centre Toronto Ontario Canada; 7. Department of Biostatistics Princess Margaret Cancer Centre University Health Network Toronto Ontario CanadaShow moreShow less
41
days
GPRC5D‐targeting bispecific and trispecific antibodies in multiple myeloma: Current evidence and emerging strategies
Authors
Darren Pan; Anupama Kumar; Jodi J. Lipof; Alfred Chung; Jeffrey L. Wolf; Thomas G. Martin; Shagun Arora; Peter H. Sayre; Ajai ChariShow moreShow less
Affiliations
1. Department of Medicine University of California San Francisco California USAShow moreShow less
79
days
Adjuvant CDK4/6 inhibitors in early‐stage breast cancer: Clinical evidence and considerations for risk stratification and treatment selection
Authors
Austin D. Williams; Anna WeissShow moreShow less
Affiliations
1. Division of Breast Surgery Department of Surgery Fox Chase Cancer Center Philadelphia Pennsylvania USA; 2. Pluta Cancer Center University of Rochester Rochester New York USAShow moreShow less
71
days
The past, present, and future treatment of BRAF V600 ‐mutant metastatic colorectal cancer: A comprehensive review
Authors
Iris Dirven; Celina Ang; Cleo Bertels; Koen Kortbeek; Amy de Haar‐Holleman; Marieke Vollebergh; Poulikos Poulikakos; Bart NeynsShow moreShow less
Affiliations
1. Team Laboratory for Medical and Molecular Oncology Translational Oncology Research Center, Department of Medical Oncology, Vrije Universiteit Brussel and Universitair Ziekenhuis Brussel Brussels Belgium; 2. Division of Hematology/Oncology, Department of Medicine Tisch Cancer Institute, Mount Sinai Hospital New York New York USA; 3. Department of Medical Oncology Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital Amsterdam Netherlands; 4. Department of Gastrointestinal Oncology Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital Amsterdam Netherlands; 5. Department of Oncological Sciences The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai New York New York USAShow moreShow less
109
days
Disease‐free survival as a surrogate outcome for localized kidney cancer—A systematic review and meta‐analysis
Authors
Constanza Martinez; David Chen; Russell Leong; Nicholas Lum; Karren Xiao; Laith Almasri; Christian K. Kollmannsberger; Srinivas RamanShow moreShow less
Affiliations
1. Department of Radiation Oncology McGill University Health Center Montreal Quebec Canada; 2. Radiation Medicine Program Princess Margaret Hospital Cancer Center Toronto Ontario Canada; 3. Temerty Faculty of Medicine University of Toronto Toronto Ontario Canada; 4. Faculty of Medicine University of Ottawa Ottawa Ontario Canada; 5. Department of Medical Oncology British Columbia Cancer Vancouver Vancouver British Columbia Canada; 6. Department of Radiation Oncology British Columbia Cancer Vancouver Vancouver British Columbia CanadaShow moreShow less
89
days
Optimizing safety and efficacy of asparaginase and blinatumomab therapy in frontline acute lymphoblastic leukemia regimens in diverse health care settings—international expert consensus
Authors
Daniel J. DeAngelo; Anna Avagyan; Jeanine Alfaro; Valentino Conter; Maria L. de Martino Lee; Łukasz Hutnik; Miriam Hwang; Hiroto Inaba; Atsushi Manabe; Jae H. Park; Rob Pieters; Carmelo Rizzari; Vaskar Saha; David T. Teachey; Inge M. van der Sluis; Scott C. HowardShow moreShow less
Affiliations
1. Department of Medical Oncology Dana‐Farber Cancer Institute Boston Massachusetts USA; 2. Pediatric Cancer and Blood Disease Center Yeolan Hematology and Oncology Center Yerevan Armenia; 3. Department of Pediatrics Unidad Nacional de Oncología Pediatrica Guatemala City Guatemala; 4. Tettamanti Center IRCCS San Gerardo dei Tintori Monza Italy; 5. Beneficência Portuguesa de São Paulo Sao Paulo Brazil; 6. Pediatric Oncology, Hematology and Clinical Transplantology Medical University of Warsaw Warsaw Poland; 7. Resonance Memphis Tennessee USA; 8. Department of Oncology St Jude Children’s Research Hospital Memphis Tennessee USA; 9. Department of Pediatrics Hokkaido University Graduate School of Medicine Hokkaido Japan; 10. Department of Medicine Memorial Sloan Kettering Cancer Center New York New York USA; 11. Princess Máxima Center for Pediatric Oncology Utrecht Netherlands; 12. Pediatric Hematology‐Oncology Unit IRCCS San Gerardo dei Tintori Monza Italy; 13. Division of Cancer Sciences University of Manchester School of Medicine Manchester UK; 14. Center for Childhood Cancer Research Children’s Hospital of Philadelphia Philadelphia Pennsylvania USA; 15. Yeolyan Hematology‐Oncology Center Yerevan ArmeniaShow moreShow less
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review62 days
Median65 days